Gary S. Roubin
Known title: DirectorCIK: 0001162533
Gary S. Roubin's purchase track record
How the stock did after each of Gary S. Roubin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 8 since August 25, 2021
Stock higher 6 months later
29%
3 months: 38%
Median 6-month return
-30.5%
3 months: -7.3%
Beat the S&P 500
14%
median -23.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/7/2026 | NSPR | $106K | -37.9% | pending | — |
| 7/30/2025 | NSPR | $100K | -4.2% | -30.4% | +9.7% |
| 11/30/2023 | NSPR | $127K | +19.1% | +10.8% | +14.6% |
| 5/12/2023 | NSPR | $100K | +121.4% | +116.5% | +7.1% |
| 8/18/2022 | NSPR | $68K | -45.8% | -30.5% | -4.5% |
| 12/28/2021 | NSPR | $50K | +7.0% | -33.8% | -20.2% |
| 11/17/2021 | NSPR | $100K | -29.7% | -39.5% | -16.3% |
| 8/25/2021 | NSPR | $93K | -10.4% | -42.0% | -6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NSPR | ▲ Buy | Open Market | 90,000 | $106K | 5/7/2026 | View on chart |
| NSPR | ▲ Buy | Grant | 88,053 | $0 | 1/14/2026 | View on chart |
| NSPR | ▲ Buy | Grant | 48,000 | $0 | 10/7/2025 | View on chart |
| NSPR | ▲ Buy | Open Market | 41,322 | $100K | 7/30/2025 | View on chart |
| NSPR | ▼ Sell | Other | 30,624 | $42K | 6/25/2025 | View on chart |
| NSPR | ▲ Buy | Grant | 32,491 | $0 | 1/7/2025 | View on chart |
| NSPR | ▼ Sell | Other | 30,625 | $42K | 5/28/2024 | View on chart |
| NSPR | ▲ Buy | Grant | 29,032 | $0 | 1/23/2024 | View on chart |
| NSPR | ▲ Buy | Grant | 3,229 | $0 | 1/2/2024 | View on chart |
| NSPR | ▲ Buy | Open Market | 50,000 | $127K | 11/30/2023 | View on chart |
| NSPR | ▲ Buy | Grant | 2,652 | $0 | 10/2/2023 | View on chart |
| NSPR | ▲ Buy | Grant | 3,445 | $0 | 7/1/2023 | View on chart |
| NSPR | ▲ Buy | Grant | 149,260 | $0 | 5/17/2023 | View on chart |
| NSPR | ▲ Buy | Open Market | 61,249 | $100K | 5/12/2023 | View on chart |
| NSPR | ▲ Buy | Grant | 8,102 | $0 | 4/1/2023 | View on chart |
| NSPR | ▲ Buy | Open Market | 35,500 | $68K | 8/18/2022 | View on chart |
| NSPR | ▲ Buy | Open Market | 16,393 | $50K | 12/28/2021 | View on chart |
| NSPR | ▲ Buy | Open Market | 25,640 | $99K | 11/17/2021 | View on chart |
| NSPR | ▲ Buy | Open Market | 290 | $1K | 11/17/2021 | View on chart |
| NSPR | ▲ Buy | Grant | 17,248 | $0 | 10/13/2021 | View on chart |
| NSPR | ▲ Buy | Open Market | 22,249 | $93K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
InspireMD (NSPR) noted in pre‑market health‑care stock moves
NSPR was listed among twelve health‑care companies showing price action in Friday’s pre‑market session, according to Benzinga. The move comes while the stock’s RSI is low at 25.7 and it is near its $0.70 support level, suggesting continued pressure. Such activity may reflect renewed trader attention despite the broader market context.
InspireMD (NSPR) noted in pre‑market health‑care stock moves. NSPR was listed among twelve health‑care companies showing price action in Friday’s pre‑market session, according to Benzinga. The move comes while the stock’s RSI is low at 25.7 and it is near its $0.70 support level, suggesting continued pressure. Such activity may reflect renewed trader attention despite the broader market context.